Processa Pharmaceuticals, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents
Processa Pharmaceuticals, Inc. (PCSA) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents of $6.28 thousand as of 2019-12-31, per its 10-K filed 2020-03-06.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents · last filed 2020-03-06
- 2019-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $6.28K.
- 2018-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $6.28K.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents |
|---|---|
| 2019-12-31 | $6.28K 10-K · filed 2020-03-06 |
| 2018-12-31 | $6.28K 10-K/A · filed 2019-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |